Navigation Links
QRxPharma Granted Additional US Patent on MoxDuo®
Date:5/23/2012

SYDNEY and BEDMINSTER, N.J., May 23, 2012 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023.  This patent covers a method of treatment of pain comprising the administration of the oral Dual Opioid® compositions of MoxDuo IR (Immediate Release) for the treatment of acute pain as well as MoxDuo CR (Controlled Release) for the treatment of chronic pain.

"This patent is a key component of our intellectual property (IP) portfolio that provides long term market exclusivity for QRxPharma's MoxDuo opioid products for the treatment of acute and chronic pain," said Dr. John Holaday, Managing Director and Chief Executive Officer.  "This issued patent expands our global IP protection as we look to the commercialisation of our first product, MoxDuo IR, in the third quarter of this year."

The original composition of matter patent granted by the USPTO (U.S. Patent No. 6,310,072) covers the combination of morphine and oxycodone and provides coverage until 2016.  The newly issued patent is directed to a method of treatment of pain using MoxDuo's composition as defined ratio of morphine/oxycodone (3/2), and will not expire until 2023.  Further patents granted in 2011 (U.S. Patents Nos. 7,923,453 and 8,012,990) extend MoxDuo IR IP protection to 2029 and cover a proprietary dosing algorithm for converting patients from intravenous opioid administration to MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.

In April, QRxPharma announced the successful completion of two Phase 1 studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilising a 3:2 ratio of morphine and oxycodone.  The proprietary MoxDuo CR formulation, encompassing both sustained delivery technology as well as abuse deterrent and
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  SI-BONE, Inc., a medical device company that pioneered the ... invasive surgical (MIS) device indicated for fusion for certain disorders ... its European operations with the formation of a GmbH and ... Manager, Germany.  Mr. Schaber will join former Kyphon colleague ... , Middle East and Asia ...
(Date:10/1/2014)... , Suisse, October 1, 2014 ... clinique et dans le domaine de l,analyse des ... lancé aujourd,hui une solution de diagnostic in vitro ... une analyse complète de la mucoviscidose dans un ... et de caractériser tous les types de variantes ...
(Date:9/30/2014)... This report analyzes the worldwide markets for Enteral ... Enteral Feeding Pumps, Nasogastric Tubes, and Others. The ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. The report ...
Breaking Medicine Technology:SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19
... BRUNSWICK, N.J., Sept. 30 Savient Pharmaceuticals, Inc. (Nasdaq: ... Court for the Southern District of New York has dismissed ... captioned Richard Sagall vs. Savient Pharmaceuticals, Inc., et al. ... The suit alleged that the Company made false and misleading ...
... HHS, Agency for Healthcare Research and Quality today ... contracts to support projects that will help people make ... effectiveness. The funding announced today covers all of AHRQ,s ... by AHRQ.   The projects will support ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit 2HHS Awards $473 Million in Patient-Centered Outcomes Research Funding 2
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining how ... family members. , Life insurance plans provide important financial ... should always carry a life insurance policy as their ... the family. , Clients can choose from several ... coverage or from a permanent policy. No medical exam ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Scientists at ... three drugs that target immune system proteins has the ... has just posted details of the new study on ... now. , Researchers in the UWA School of ... anti-CTLA-4 drugs to mice with mesothelioma with promising results. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Woodland ... speak to a group of dental specialists who treat ... northern Spain city of Oviedo. Dr. Reshad of the ... lecturer with clients on two continents, will give a ... aesthetic full mouth reconstruction. , “These specialists want to ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... the combination of chemotherapy with a new medication could ... the study of close to 1,000 patients, the overall ... chemotherapy and the oral drug uracil-tegafur. Results of the ... died within five years compared to 89 patients who ...
... Researchers say , the leading cause of blindness for ... macular degeneration // is the leading cause of blindness ... causes of blindness for blacks. ,More than 50 ... because of macular degeneration. In contrast, more than 60 ...
... Americans undergo balloon angioplasty to clear blocked arteries. In many ... may change the outcome of the procedure. ,John ... to avoid a second open-heart surgery. Eight years ago, he ... this year, Bailey had the same kind of chest pain. ...
... on the results of a recent study researchers offer ... of stretching before exercising.// Specialists say stretching does not ... shows static stretching makes muscles weaker for 10 to ... injury. They say some likely causes of injuries include ...
... Diabetic retinopathy is one of the leading causes of blindness ... the retina and the light-sensitive // layer of cells at ... with long-standing diabetes but its incidence can be reduced with ... shows approximately 4.1 million Americans, age 40 or older, suffer ...
... to offer good news for older adults .The first ... in the elderly. Researchers studied nearly 140 adults over ... major depression, while the other half suffered from minor ... had an annual income of less than $10,000. ...
Cached Medicine News:
... Our Shortest, Lightest Pipettor , , The ... perfect example of how our face-to-face relationship with ... new products that make pipetting easier and more ... single channel pipettors., Gets you closer to ...
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
Inquire...
Medicine Products: